We were pleased to read the recent article by Poto et al. entitled “Effectiveness of tezepelumab in severe asthma: A multicenter real-world study,” published in the European Journal of Internal Medicine [1]. The authors provide valuable real-world evidence on the efficacy and safety of tezepelumab in severe asthma, reporting meaningful improvements in asthma control, oral corticosteroid use, exacerbation frequency, and type 2 inflammatory biomarkers. Their results are consistent with earlier randomized trials and add useful insights to the growing real-world experience with this agent.
